IPW
GRCE

Impact Partnership Wealth’s Grace Therapeutics GRCE Stock Holding History

Impact Partnership Wealth’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10
Closed -$28 – 1111
2023
Q3 		$28 Buy
+10
New +$24 ﹤0.01% 980

Other funds holding GRCE

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
IGWM
ICA Group Wealth Management Denver, Colorado $167M AUM 18.57% 1-Year Est. Return

Impact Partnership Wealth's GRCE Position: Q4 2023 in Review

Impact Partnership Wealth sold out of Grace Therapeutics (GRCE) in Q4 2023, closing a stake of 10 shares — an estimated $28 sold.

Impact Partnership Wealth first reported a position in GRCE in Q3 2023 and held it in 1 quarter. The position peaked at $28 in Q3 2023. 9 funds tracked by Wall St. Rank hold GRCE as of Q4 2023.

  • Impact Partnership Wealth reported no remaining Grace Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Impact Partnership Wealth sold 10 Grace Therapeutics shares in Q4 2023, an estimated $28.
  • Impact Partnership Wealth first reported a position in Grace Therapeutics in Q3 2023 and held it in 1 quarter.
  • Impact Partnership Wealth's Grace Therapeutics position peaked at $28 in Q3 2023.
  • 9 funds tracked by Wall St. Rank held Grace Therapeutics as of Q4 2023.

Based on Impact Partnership Wealth's 13F filing for Q4 2023, filed 14 Feb 2024.